Mining Complex Biomedical Literature for Actionable Knowledge on Rare Diseases
暂无分享,去创建一个
Anthony J. Hickey | Nancy C. Baker | Eugene Muratov | Vinicius M. Alves | Stephen J. Capuzzi | Alexander Trospsha | Nancy C. Baker | Stephen J. Capuzzi | Vinicius M. Alves | E. Muratov | A. Hickey | Alexander Trospsha
[1] J. Brownstein,et al. Social and news media enable estimation of epidemiological patterns early in the 2010 Haitian cholera outbreak. , 2012, The American journal of tropical medicine and hygiene.
[2] Ireneus Kagashe,et al. Enhancing Seasonal Influenza Surveillance: Topic Analysis of Widely Used Medicinal Drugs Using Twitter Data , 2017, Journal of medical Internet research.
[3] Peter J. Haas,et al. Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2 , 2018, Proceedings of the National Academy of Sciences.
[4] Jahan B Ghasemi,et al. Combating Diseases with Computational Strategies Used for Drug Design and Discovery. , 2018, Current topics in medicinal chemistry.
[5] Riccardo Bellazzi,et al. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer , 2016, PloS one.
[6] Sean Ekins,et al. A bibliometric review of drug repurposing. , 2018, Drug discovery today.
[7] K. Bretonnel Cohen,et al. Large-scale biomedical concept recognition: an evaluation of current automatic annotators and their parameters , 2014, BMC Bioinformatics.
[8] Peng Sun,et al. Drug repurposing by integrated literature mining and drug-gene-disease triangulation. , 2017, Drug discovery today.
[9] Anne R. Pariser,et al. From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research , 2018, Orphanet Journal of Rare Diseases.
[10] A. Mantel‐Teeuwisse,et al. Drug repositioning and repurposing: terminology and definitions in literature. , 2015, Drug discovery today.
[11] A. Marchevsky,et al. Presence of c-KIT-positive mast cells in obliterative bronchiolitis from diverse causes. , 2009, Archives of pathology & laboratory medicine.
[12] Nicola Nosengo. Can you teach old drugs new tricks? , 2016, Nature.
[13] P. Sanseau,et al. Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.
[14] Colin P O'Banion,et al. Chemotext: A Publicly Available Web Server for Mining Drug-Target-Disease Relationships in PubMed , 2018, J. Chem. Inf. Model..
[15] A. Tropsha,et al. Predicting Adverse Drug Effects from Literature- and Database-Mined Assertions , 2018, Drug Safety.
[16] Sophia Ananiadou,et al. SciLite: a platform for displaying text-mined annotations as a means to link research articles with biological data , 2017, Wellcome open research.
[17] Sean Ekins,et al. Industrializing rare disease therapy discovery and development , 2017, Nature Biotechnology.
[18] Bradley M. Hemminger,et al. Mining connections between chemicals, proteins, and diseases extracted from Medline annotations , 2010, J. Biomed. Informatics.
[19] Bruno J. Neves,et al. In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against Multiple Life Stages of Schistosoma mansoni , 2015, PLoS neglected tropical diseases.
[20] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[21] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[22] Lawrence Hunter,et al. Knowledge-based biomedical Data Science , 2017, Data Sci..
[23] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[24] Abhishek Pandey,et al. Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review , 2017, J. Biomed. Informatics.
[25] Christopher M. Danforth,et al. Forecasting the onset and course of mental illness with Twitter data , 2016, Scientific Reports.
[26] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[27] Bin Chen,et al. The ChEMBL database as linked open data , 2013, Journal of Cheminformatics.
[28] Shang Gao,et al. Integrating text mining, data mining, and network analysis for identifying genetic breast cancer trends , 2016, BMC Research Notes.
[29] Janine Lewis,et al. Marking 15 years of the Genetic and Rare Diseases Information Center , 2017, Translational science of rare diseases.
[30] P. Reichardt. The Story of Imatinib in GIST - a Journey through the Development of a Targeted Therapy , 2018, Oncology Research and Treatment.
[31] Alexander Golbraikh,et al. Multi-Descriptor Read Across (MuDRA): A Simple and Transparent Approach for Developing Accurate Quantitative Structure-Activity Relationship Models , 2018, J. Chem. Inf. Model..
[32] R. Valdez,et al. Public Health and Rare Diseases: Oxymoron No More , 2016, Preventing chronic disease.
[33] Bridget T. McInnes,et al. Literature Based Discovery: Models, methods, and trends , 2017, J. Biomed. Informatics.
[34] E. Abraham,et al. Metformin reverses established lung fibrosis in a bleomycin model , 2018, Nature Medicine.
[35] John R. Rumble,et al. Development of the web-based NIST X-ray Photoelectron Spectroscopy (XPS) Database , 2002, Data Sci. J..
[36] Ross D. King,et al. Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases , 2015, Journal of The Royal Society Interface.
[37] Ronald N. Kostoff,et al. Literature-related discovery (LRD): Potential treatments for Multiple Sclerosis , 2008 .
[38] Didier Rognan,et al. The impact of in silico screening in the discovery of novel and safer drug candidates. , 2017, Pharmacology & therapeutics.
[39] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[40] R. J. Roberts. PubMed Central: The GenBank of the published literature. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] Yoonjeong Cha,et al. Pharma Perspective on Drug Repurposing , 2017 .
[42] M. Might,et al. Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease. , 2017, Bioorganic & medicinal chemistry letters.
[43] Natalia Novac,et al. Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.
[44] E. Klann,et al. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model , 2018, Neuropsychopharmacology.
[45] Ronald N. Kostoff,et al. Literature-Related Discovery (LRD): Potential treatments for Parkinson's Disease , 2008 .
[46] A. Markham,et al. Sildenafil: a review of its use in erectile dysfunction. , 1999, Drugs.
[47] Sophia Ananiadou,et al. Text mining resources for the life sciences , 2016, Database J. Biol. Databases Curation.
[48] W. Tong,et al. Computational drug repositioning for rare diseases in the era of precision medicine. , 2017, Drug discovery today.
[49] Domenica Taruscio,et al. Data Quality in Rare Diseases Registries. , 2017, Advances in experimental medicine and biology.
[50] Doron Lancet,et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search , 2016, Nucleic Acids Res..
[51] Zhiyong Lu,et al. PubTator: a web-based text mining tool for assisting biocuration , 2013, Nucleic Acids Res..
[52] Xianting Ding,et al. Drug screening: Drug repositioning needs a rethink , 2016, Nature.
[53] Rajarshi Guha,et al. Pharos: Collating protein information to shed light on the druggable genome , 2016, Nucleic Acids Res..
[54] Michal Brylinski,et al. Large-scale computational drug repositioning to find treatments for rare diseases , 2018, npj Systems Biology and Applications.
[55] Alexander Tropsha,et al. Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation , 2016, J. Chem. Inf. Model..
[56] Graeme Hirst,et al. Utility of social media and crowd-intelligence data for pharmacovigilance: a scoping review , 2018, BMC Medical Informatics and Decision Making.
[57] Chunlei Liu,et al. ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..
[58] J. Arrowsmith. Trial watch: Phase II failures: 2008–2010 , 2011, Nature Reviews Drug Discovery.
[59] D. Swanson. Migraine and Magnesium: Eleven Neglected Connections , 2015, Perspectives in biology and medicine.
[60] Leonardo L. G. Ferreira,et al. Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. , 2016, Drug discovery today.
[61] Alexander Tropsha,et al. Curation of chemogenomics data. , 2015, Nature chemical biology.
[62] Sharon F Terry,et al. An End to the Myth: There Is No Drug Development Pipeline , 2013, Science Translational Medicine.
[63] George Papadatos,et al. The ChEMBL database in 2017 , 2016, Nucleic Acids Res..
[64] Todd J. Bodnar,et al. Identifying Adverse Effects of HIV Drug Treatment and Associated Sentiments Using Twitter , 2015, JMIR public health and surveillance.
[65] S. Rees,et al. Principles of early drug discovery , 2011, British journal of pharmacology.
[66] R. W. Hansen,et al. Journal of Health Economics , 2016 .
[67] Dong-Qing Wei,et al. Rare Diseases: Drug Discovery and Informatics Resource , 2017, Interdisciplinary Sciences: Computational Life Sciences.
[68] G. Spyrou,et al. Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score , 2017, Scientific Reports.
[69] S. Ekins,et al. Collaboration for rare disease drug discovery research , 2014, F1000Research.
[70] Jie Zhou,et al. The research on gene-disease association based on text-mining of PubMed , 2018, BMC Bioinformatics.
[71] Polina Mamoshina,et al. Design of efficient computational workflows for in silico drug repurposing. , 2017, Drug discovery today.
[72] Sean Ekins,et al. In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.
[73] Aris Angelis,et al. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. , 2015, Health policy.
[74] Mark D. Wilkinson,et al. Preparing Data at the Source to Foster Interoperability across Rare Disease Resources. , 2017, Advances in experimental medicine and biology.
[75] Antonio Jimeno-Yepes,et al. Detection of adverse drug reactions using medical named entities on Twitter , 2017, AMIA.
[76] S. Papapetropoulos,et al. Drug repurposing from the perspective of pharmaceutical companies , 2018, British journal of pharmacology.
[77] Allison Crosby-Thompson,et al. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma , 2017, The New England journal of medicine.
[78] Wei Pan,et al. The New Hardware Development Trend and the Challenges in Data Management and Analysis , 2018, Data Science and Engineering.
[79] A. Simeonov,et al. Drug discovery and development for rare genetic disorders , 2017, American journal of medical genetics. Part A.
[80] Michael Pryszlak,et al. Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics , 2017, Front. Oncol..
[81] F. Goodsaid,et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints , 2015, Orphanet Journal of Rare Diseases.